Skip to content

Study · Randomized controlled trial · 2003

4 results

A randomized, placebo-controlled, dose-ranging trial comparing fulvestrant with goserelin in premenopausal patients with uterine fibroids awaiting hysterectomy.

Donnez J, Hervais Vivancos B, Kudela M, Audebert A, Jadoul P

Fertility and sterility1 Jun 2003Cited by 37 (Europe PMC)

PMID12798886 (opens in a new tab)DOI10.1016/s0015-0282(03)00261-9 (opens in a new tab)PepBankPUB-12798886
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In premenopausal women with uterine fibroids, goserelin significantly reduced fibroid growth compared with placebos.

    In plain wordsIn premenopausal women with uterine fibroids, goserelin reduced fibroid growth compared with placebos.

    Peptide
    Goserelin
    Outcome
    DecreaseFibroid growth
    Study

    n: not reported in source

    Comparator
    Placebos
    Outcome group
    Tumor growth · Reproductive and sexual health
    Studied dose
    3.6 mg once every 4 weeks · subcutaneous · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Goserelin significantly reduced fibroid growth and endometrial thickness compared with placebos.
    3 context sentences
    Summary · context
    An international, multicenter, randomized, placebo-controlled study.
    Summary · context
    Premenopausal women (n = 307) diagnosed with uterine fibroids requiring hysterectomy.
    Summary · context
    Over a 12-week period, patients received fulvestrant (50 mg, 125 mg, or 250 mg) as an i.m. injection, goserelin (3.6 mg) as a s.c. injection, or an injection-matched placebo once every 4 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In premenopausal women with uterine fibroids, goserelin significantly reduced endometrial thickness compared with placebos.

    In plain wordsIn premenopausal women with uterine fibroids, goserelin reduced womb lining thickness compared with placebos.

    Peptide
    Goserelin
    Outcome
    DecreaseEndometrial thickness
    Study

    n: not reported in source

    Comparator
    Placebos
    Outcome group
    Endometrial Thickness · Reproductive and sexual health
    Studied dose
    3.6 mg once every 4 weeks · subcutaneous · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Goserelin significantly reduced fibroid growth and endometrial thickness compared with placebos.
    3 context sentences
    Summary · context
    An international, multicenter, randomized, placebo-controlled study.
    Summary · context
    Premenopausal women (n = 307) diagnosed with uterine fibroids requiring hysterectomy.
    Summary · context
    Over a 12-week period, patients received fulvestrant (50 mg, 125 mg, or 250 mg) as an i.m. injection, goserelin (3.6 mg) as a s.c. injection, or an injection-matched placebo once every 4 weeks.
  3. 03HumanRandomized controlled trialSafety outcome

    In premenopausal women with uterine fibroids, postmenopause-related adverse events were more frequent with goserelin than fulvestrant.

    In plain wordsIn premenopausal women with uterine fibroids, menopause-related side effects were more common with goserelin than fulvestrant.

    Peptide
    Goserelin
    Outcome
    IncreasePostmenopause-related adverse events
    Study

    n: not reported in source

    Comparator
    Fulvestrant
    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    3.6 mg once every 4 weeks · subcutaneous · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Fulvestrant was associated with fewer postmenopause-related adverse events than goserelin.
    3 context sentences
    Summary · context
    An international, multicenter, randomized, placebo-controlled study.
    Summary · context
    Premenopausal women (n = 307) diagnosed with uterine fibroids requiring hysterectomy.
    Summary · context
    Over a 12-week period, patients received fulvestrant (50 mg, 125 mg, or 250 mg) as an i.m. injection, goserelin (3.6 mg) as a s.c. injection, or an injection-matched placebo once every 4 weeks.
  4. 04HumanRandomized controlled trialSafety outcome

    In premenopausal women with uterine fibroids, goserelin significantly increased markers of bone resorption, whereas fulvestrant did not.

    In plain wordsIn premenopausal women with uterine fibroids, goserelin increased markers of bone breakdown, whereas fulvestrant did not.

    Peptide
    Goserelin
    Outcome
    IncreaseBone resorption markers
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    3.6 mg once every 4 weeks · subcutaneous · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Goserelin, but not fulvestrant, significantly increased markers of bone resorption.
    3 context sentences
    Summary · context
    An international, multicenter, randomized, placebo-controlled study.
    Summary · context
    Premenopausal women (n = 307) diagnosed with uterine fibroids requiring hysterectomy.
    Summary · context
    Over a 12-week period, patients received fulvestrant (50 mg, 125 mg, or 250 mg) as an i.m. injection, goserelin (3.6 mg) as a s.c. injection, or an injection-matched placebo once every 4 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.